

Variant: NM_001130987.2(DYSF):c.5687A>G (p.His1896Arg)

Version: 1.0

CA49769275 [↗](#)

2441110 (ClinVar) [↗](#)

Gene: DYSF ([HGNC:8291](#))

Condition: autosomal recessive limb-girdle muscular dystrophy
([MONDO:0015152](#))

Inheritance Mode: Autosomal recessive inheritance

UUID: 872d4ee1-6a57-4044-858d-000ae2f85102

Approved on: 2026/4/1

Published on: 2026/5/7

HGVS expressions

NM_001130987.2:c.5687A>G

NM_001130987.2(DYSF):c.5687A>G (p.His1896Arg)

NC_000002.12:g.71669649A>G

CM000664.2:g.71669649A>G

NC_000002.11:g.71896779A>G

CM000664.1:g.71896779A>G

NC_000002.10:g.71750287A>G

NG_008694.1:g.221027A>G

ENST00000698057.1:c.3101A>G

ENST00000698058.1:c.2318A>G

ENST00000698059.1:c.2426A>G

ENST00000258104.8:c.5570A>G

ENST00000410020.8:c.5687A>G

ENST00000258104.7:c.5570A>G

ENST00000394120.6:c.5573A>G

ENST00000409366.5:c.5636A>G

ENST00000409582.7:c.5684A>G

ENST00000409651.5:c.5666A>G

ENST00000409744.5:c.5594A>G

ENST00000409762.5:c.5621A>G

ENST00000410020.7:c.5687A>G

ENST00000410041.1:c.5624A>G

ENST00000413539.6:c.5663A>G

ENST00000429174.6:c.5633A>G

ENST00000479049.6:n.2455A>G

NM_001130455.1:c.5573A>G

NM_001130976.1:c.5528A>G

NM_001130977.1:c.5591A>G

NM_001130978.1:c.5633A>G

NM_001130979.1:c.5663A>G

NM_001130980.1:c.5621A>G

NM_001130981.1:c.5684A>G

NM_001130982.1:c.5666A>G

NM_001130983.1:c.5636A>G

NM_001130984.1:c.5594A>G

NM_001130985.1:c.5624A>G

NM_001130986.1:c.5531A>G

NM_001130987.1:c.5687A>G
NM_003494.3:c.5570A>G
NM_001130455.2:c.5573A>G
NM_001130976.2:c.5528A>G
NM_001130977.2:c.5591A>G
NM_001130978.2:c.5633A>G
NM_001130979.2:c.5663A>G
NM_001130980.2:c.5621A>G
NM_001130981.2:c.5684A>G
NM_001130982.2:c.5666A>G
NM_001130983.2:c.5636A>G
NM_001130984.2:c.5594A>G
NM_001130985.2:c.5624A>G
NM_001130986.2:c.5531A>G
NM_003494.4:c.5570A>G

Pathogenic

Met criteria codes 4

- PM2_Supporting
- PP3
- PM3_Strong
- PP4_Strong

Not Met criteria codes 4

- PS1
- PS3
- PP1
- PM5

Evidence Links 0

Expert Panel

Limb Girdle Muscular Dystrophy VCEP

Criteria Specification Information

- [Criteria Specification:](#) ClinGen Limb Girdle Muscular Dystrophy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for DYSF Version 2.0.0
- [Criteria Specification Approval History](#)
- [Criteria Specifications for this VCEP](#)

Evidence submitted by expert panel

Limb Girdle Muscular Dystrophy VCEP

The NM_003494.4: c.5570A>G variant in DYSF, which is also known as NM_001130987.2: c.5687A>G p.(His1896Arg), is a missense variant predicted to cause the substitution of histidine with arginine at amino acid 1857, p.(His1857Arg). This variant has been identified in at least five unrelated individuals with features consistent with LGMD (PMID: 30564623, 36319958, 11468312, 9731526; ClinVar SCV004292580.2 internal data communication). These reports include one homozygous patient without reported consanguinity (0.5 pts, ClinVar SCV004292580.2 internal data communication) and three patients where it was reported in unconfirmed phase with a pathogenic variant (NM_003494.4: c.2779del (p.Ala927LeufsTer21), 0.5 pts, PMID: 30564623, LOVD Individual #00222471; c.156G>A p.(Trp52Ter), 0.5 pts, PMID: 36319958; c.1129C>T p.(Arg377Ter), 0.5 pts, ClinVar SCV004292580.2 internal data communication) (PM3_Strong). At least one patient with this variant and a second presumed diagnostic DYSF variant displayed both progressive limb girdle muscle weakness and strongly reduced dysferlin protein expression in skeletal muscle, which is highly specific for DYSF-related LGMD (PMID: 36319958; PP4_Strong). The upper bound of the 95% confidence interval of the Grpmax variant allele frequency is 0.000006751 in gnomAD v4.1.0 (3/1180062 European (non-Finnish) chromosomes), which is less than the ClinGen LGMD VCEP threshold (<0.0001) (PM2_Supporting). The computational predictor REVEL gives a score of 0.929, which is above the LGMD VCEP threshold of ≥0.70, evidence that correlates with impact to DYSF function (PP3). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive limb girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the LGMD VCEP (specifications v2.0.0; 04/01/2026): PM3_Strong, PP4_Strong, PM2_Supporting, PP3.

Met criteria codes

PM2_Supporting			The upper bound of the 95% confidence interval of the Grpmax variant allele frequency is 0.000006751 in gnomAD v4.1.0 (3/1180062 European (non-Finnish) chromosomes), which is less than the ClinGen LGMD VCEP threshold (<0.0001) (PM2_Supporting).
PP3			The computational predictor REVEL gives a score of 0.929, which is above the LGMD VCEP threshold of ≥ 0.70 , evidence that correlates with impact to DYSF function (PP3). SpliceAI: no splice effect.
PM3_Strong			This variant has been identified in at least five unrelated individuals with features consistent with LGMD (PMID: 30564623, 36319958, 11468312, 9731526; ClinVar SCV004292580.2 internal data communication). These reports include one homozygous patient without reported consanguinity (0.5 pts, ClinVar SCV004292580.2 internal data communication) and three patients where it was reported in unconfirmed phase with a pathogenic variant (NM_003494.4: c.2779del (p.Ala927LeufsTer21), 0.5 pts, PMID: 30564623, LOVD Individual #00222471; c.156G>A p.(Trp52Ter), 0.5 pts, PMID: 36319958; c.1129C>T p.(Arg377Ter), 0.5 pts, ClinVar SCV004292580.2 internal data communication) (PM3_Strong). Co-occurrence: c.156G>A p.(Trp52Ter) (c.159G>A p.(Trp53Ter)): not observed in gnomAD v2, no prediction possible c.2779del p.(Ala927LeufsTer21): predicted on different haplotypes c.1129C>T p.(Arg377Ter): predicted on different haplotypes
PP4_Strong			At least one patient with this variant and a second presumed diagnostic DYSF variant displayed both progressive limb girdle muscle weakness and strongly reduced dysferlin protein expression in skeletal muscle, which is highly specific for DYSF-related LGMD (PMID: 36319958; PP4_Strong).
Not Met criteria codes			
PS1			no relevant variant identified All the variants at His1896 change the amino acid to something different: His → Tyr His → Arg His → Leu
PS3			Not evaluated in Tominaga et al. (2022).
PP1			Likely one affected family member with the same genotype, but phase not confirmed (ClinVar SCV004292580.2 internal data communication).
PM5			No other clear P/LP variant at this position

Curation History 



▼

▼

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.